Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) reported 2025 annual results, with operating revenue rising 13.02% YoY to RMB 31.629 billion (USD 4.58 billion) and net profit (recurring) jumping 20.00% to RMB 7.413 billion (USD 1.074 billion). Innovative drugs now dominate revenue mix at 58.34%, with out-licensing emerging as a routine business segment generating RMB 3.392 billion (USD 491 million) through 5 major global deals including GSK, Merck & Co., and IDEAYA Biosciences.
Forward‑Looking Statements This brief contains forward‑looking statements regarding 2026–2028 product approvals, out-licensing sustainability, and global partnership expansion. Actual results may differ due to NMPA review timelines, competitive dynamics in oncology and metabolic diseases, and geopolitical factors affecting China-origin pharmaceutical exports.-Fineline Info & Tech
